Syros Pharmaceuticals Inc (NAS:SYRS)
$ 1.5675 -0.035 (-2.18%) Market Cap: 42.02 Mil Enterprise Value: 24.59 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Syros Pharmaceuticals Inc at ESMO Congress Conference Call Transcript

Sep 20, 2021 / 08:00PM GMT
Release Date Price: $49.8 (-1.97%)
Operator

Thank you for standing by, and welcome to the Syros Pharmaceuticals Conference Call. (Operator Instructions) As a reminder, today's conference call may be recorded. I will now turn the conference to your host, Ms. Nancy Simonian. Please go ahead.

Nancy A. Simonian
Syros Pharmaceuticals, Inc. - President, CEO, Interim Principal Financial & Accounting Officer and Director

Great. Thank you for joining us today to review the SY-5609 Phase I dose escalation data and next steps. Dr. David Roth, our Chief Medical Officer; and Kristin Stephens, our Chief Development Officer, are also on the call, as is Dr. Eric Olson, our Chief Scientific Officer, who will be available for Q&A.

Next slide. Before we begin, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Any forward-looking statements made on this call represent our views only as of today. Actual events or results could differ materially as a result of various risks, uncertainties and other factors, including those risk factors

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot